The News
Ginkgo Bioworks is transitioning to a fully automated laboratory infrastructure after divesting its biosecurity unit and launching new AI-driven services. This strategic pivot has raised concerns among investors, impacting the company's share price.
Why It Matters
The move towards automation reflects a broader trend in the biotech sector, emphasizing efficiency and scalability in research and development. This shift could enhance Ginkgo's competitive edge in the rapidly evolving AI landscape, particularly in biomanufacturing and synthetic biology.
Key Evidence
The information is sourced from a report by aktiencheck, which is a reliable reporting platform, though it does not indicate an official announcement from Ginkgo Bioworks.
Source
aktiencheck
DE source 路 Published 2d ago